Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.
about
Specific humoral immunity versus polyclonal B cell activation in Trypanosoma cruzi infection of susceptible and resistant mice.Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.Co-administration of a plasmid DNA encoding IL-15 improves long-term protection of a genetic vaccine against Trypanosoma cruziInduction of IL-12 production in human peripheral monocytes by Trypanosoma cruzi Is mediated by glycosylphosphatidylinositol-anchored mucin-like glycoproteins and potentiated by IFN- γ and CD40-CD40L interactions.Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infectionRecombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruziHeterologous plasmid DNA prime-recombinant human adenovirus 5 boost vaccination generates a stable pool of protective long-lived CD8(+) T effector memory cells specific for a human parasite, Trypanosoma cruziDeficiency of antigen-specific B cells results in decreased Trypanosoma cruzi systemic but not mucosal immunity due to CD8 T cell exhaustion.Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection.Oral exposure to Trypanosoma cruzi elicits a systemic CD8⁺ T cell response and protection against heterotopic challengeImmune responses to gp82 provide protection against mucosal Trypanosoma cruzi infectionECG detection of murine chagasic cardiomyopathy.Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruzi protection and B cell activation.Costimulatory Effects of an Immunodominant Parasite Antigen Paradoxically Prevent Induction of Optimal CD8 T Cell Protective Immunity.Th17 Cells Are More Protective Than Th1 Cells Against the Intracellular Parasite Trypanosoma cruziNovel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.Vaccination approaches against Trypanosoma cruzi infection.Comparison of the infectivity of Trypanosoma cruzi insect-derived metacyclic trypomastigotes after mucosal and cutaneous contaminative challenges.Perspectives of vaccination in Chagas disease revisited.Trypanosoma cruzi Entrance through Systemic or Mucosal Infection Sites Differentially Modulates Regional Immune Response Following Acute Infection in Mice.How could we have better vaccines against tuberculosis?The Unsolved Jigsaw Puzzle of the Immune Response in Chagas DiseaseInduction of proinflammatory cytokines and nitric oxide by Trypanosoma cruzi in renal cells
P2860
Q33631293-35F727AF-27F4-42BD-8B36-D0A9230E18AAQ33675887-7E1C0141-7EAF-42F4-B47B-D5E722DD64B7Q33847435-642720CF-0FFB-456D-801B-032F84198EF7Q33997924-7018D0E1-2D9D-4787-8D48-8B09F0A8C20AQ34075166-726B3FB9-57A2-4D8A-A47B-B038B6ACFF1DQ34635043-C58D6986-6DDC-4CB6-B787-68842EDE1525Q34931648-854C32EB-2460-4E70-8357-4B6E6E5D1579Q35071882-AFC2B17D-3FBD-4928-B19E-F35C67760C95Q35073839-7B949628-4F13-4420-9B28-0B2B7D6C20EFQ35139381-05FED89C-E4C4-4E70-80E1-69C523B022CFQ35148043-6BD1E74A-C28B-49DC-AB25-3BB3555C0D0EQ35148047-2B8BC7D3-89CC-4347-91C0-92ABA5CC8FD3Q35149267-86457CD4-6F72-4B23-9031-229E0B7935D8Q36136972-49D011F1-B7C8-434D-A47C-F36610ACC40EQ36151179-F037E3DC-4AB4-4C55-82E9-032B7478D345Q36844914-90934048-D6DD-4BC3-9416-36B992DA962AQ37355936-3327E454-A17F-48DC-B052-6CADF5696648Q37524046-B4AADB84-FC84-4464-8AF2-D2BD1919C866Q37675047-4326F4C8-C560-45C7-933D-C26A63D21CDAQ39945086-DB0CC463-A8B0-4300-88E0-903D252FF7D8Q41935309-50B418D7-6F95-44B9-B4DC-A4A84079856CQ57112024-393E5FED-DB7C-4547-9F3F-6E2064C3E1EBQ58705710-737624DF-6371-495E-AD0A-685445690717Q58849763-9B820175-C05A-47C3-A1B7-42623ACDED46
P2860
Type 1 immunity provides both optimal mucosal and systemic protection against a mucosally invasive, intracellular pathogen.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Type 1 immunity provides both ...... asive, intracellular pathogen.
@en
Type 1 immunity provides both ...... asive, intracellular pathogen.
@nl
type
label
Type 1 immunity provides both ...... asive, intracellular pathogen.
@en
Type 1 immunity provides both ...... asive, intracellular pathogen.
@nl
prefLabel
Type 1 immunity provides both ...... asive, intracellular pathogen.
@en
Type 1 immunity provides both ...... asive, intracellular pathogen.
@nl
P2860
P1476
Type 1 immunity provides both ...... vasive, intracellular pathogen
@en
P2093
Daniel F Hoft
P2860
P304
P356
10.1128/IAI.73.8.4934-4940.2005
P407
P50
P577
2005-08-01T00:00:00Z